Development of IL-5 Receptor Antagonists

Author(s): Iain Uings, Murray McKinnon

Journal Name: Current Pharmaceutical Design

Volume 8 , Issue 20 , 2002

Become EABM
Become Reviewer


A wealth of both clinical and pre-clinical data has strongly implicated the eosinophil in the pathogenesis of asthma, highlighting this cell type as a potential target for novel anti-inflammatory approaches to asthma therapy. The Th2 lymphocyte derived cytokine Interleukin-5 (IL-5) has emerged as the key regulator of eosinophil production, thus identifying IL-5 as the principal molecular target for therapeutic intervention. This review highlights both the pharmaceutical approaches, and the major challenges, to the identification of small molecule and protein antagonists of the IL-5 receptor. Using examples of known inhibitors we discuss their current status and highlight the major development hurdles in progressing these molecules into the market place.

Keywords: receptor antagonists, granulocyte-macrophage, bronchial hyperreactivity, constrained peptides

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [1837 - 1844]
Pages: 8
DOI: 10.2174/1381612023393800
Price: $65

Article Metrics

PDF: 1